prabotulinumtoxinA

PreclinicalSmall molecule

UUniversity of Southern California

prabotulinumtoxinA is one of 13 small molecule programs targeting Bruxism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BruxismActive, not recruiting

BruxismPreclinical

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Bruxism

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Approved

2 2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 3

XEOMIN

MMerz Pharmaceuticals GmbH

Paraflex

1 5

Xeomin

MMerz Therapeutics GmbH

Phase 3

1 6

Dysport

GGalderma R&D

Preclinical

1 7

Botox

AbbVie

Preclinical

2 8

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

2 9

Pharmacotherapy

UUniversity of Pittsburgh

Preclinical

1 10

Melissa

UUniversidade Federal do Rio de Janeiro

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glabellar Lines2 trials

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Completed·CClinical Testing of Beverly Hills·Phase 1·NCT05129319·30 enrolled

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Unknown status·UUniversity of Southern California·Phase 1·NCT04715048·20 enrolled

Bruxism1 trial

Comparison of Dry Needling and Two Botulinum Toxins for Bruxism

Active, not recruiting·RRecep Tayyip Erdogan University·N/A·NCT07452510·69 enrolled

Glabellar Frown Lines1 trial

Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Completed·EEvolus, Inc.··NCT05481931·756 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for prabotulinumtoxinA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — prabotulinumtoxinA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for prabotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Southern California

prabotulinumtoxinA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glabellar Lines2 trials

Bruxism1 trial

Glabellar Frown Lines1 trial

References

Drug Info

Quick Facts

Related News